Protocol Ledger

NCT06947928 · Phase II/III · RECRUITING

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Interventional Phase II/III clinical trial protocol NCT06947928 sponsored by TuHURA Biosciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-11 Enrollment: 118 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06947928
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)118 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06947928
Protocol FieldVerified Registry Value
NCT IdentifierNCT06947928
Consolidated Lead SponsorTuHURA Biosciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment118 participants (ESTIMATED)
Registered Start Date2025-12-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI